高齢者の急性肺炎におけるアスピリン:多施設共同、二重盲検、ランダム化、プラセボ対照試験。 (ASPAPY)
Acute pneumonia is a very common disease, and one of the leading causes of hospitalization and death in France. Almost a century after the discovery of penicillin, no major breakthrough has significantly reduced pneumonia-related mortality. While the choice of an appropriate antibiotic is decisive in the acute phase of the disease, the longer-term prognosis depends essentially on the worsening of other underlying pathologies, particularly in the elderly. In cured patients, excess mortality persists several months after the episode of pneumonia, due in particular to the onset of cardiovascular complications. Recent scientific literature shows an association between the prescription of cardio-protective drugs and survival after pneumonia. Older patients are usually excluded from interventional studies, so there are no specific recommendations for these patients at high risk of both acute pneumonia and cardiovascular events.
The aim of this study is to assess the efficacy of low-dose aspirin therapy after pneumonia in preventing cardiovascular events in the elderly.
The main objective is therefore to evaluate the impact of aspirin at a dose of 100mg per day on all-cause mortality at 90 days in patients over 75 years of age hospitalized for pneumonia.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Alain PUTOT
- 電話番号:04 50 47 30 89
- メール:a.putot@ch-sallanches-chamonix.fr
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Informed consent obtained from patient or relative/trusted person if patient unable to consent
- Age ≥75 years
- Clinical diagnosis of AP, presumed to be of bacterial or viral origin, with at least two of the following signs or symptoms:
- cough,
- purulent expectoration,
- thoracic pain,
- dyspnea/tachypnea,
- temperature > 37.8°C or < 36°C,
- unilateral crackles
- Patient hospitalized for at least 48 hours
- Onset of clinical signs < 7 days
- New radiological infiltrate documented by X-ray, ultrasound or CT scan
Exclusion Criteria:
- Mechanically ventilated pneumonia
- Documented SARS CoV2 pneumonia
- Patient with at least 3 episodes of inhalation pneumonitis in the 12 months prior to inclusion
- Pre-acute episode swallowing disorders impairing oral medication intake
- Physician-assessed life expectancy < 90 days
- Anticoagulant treatment (curative doses)
- Antiplatelet therapy
- Steroidal or non-steroidal anti-inflammatory treatment or oral corticosteroids without proton pump inhibitor (PPI)
- Treatment with methotrexate (>20 mg per week), anagrelide, probenecid, nicorandil, defibrotide
- Dyspepsia or gastroesophageal reflux disease (GERD) without PPI use
- Contraindications to aspirin (preventive doses) or its placebo at the time of inclusion:
- Hypersensitivity to acetylsalicylic acid or to any of the excipients of the investigational drug or placebo
- History of asthma induced by the administration of salicylates or non-steroidal anti-inflammatory drugs
- Active peptic ulcer disease or history of recurrent peptic ulcer disease
- History of cerebrovascular haemorrhage
- Previous gastrointestinal hemorrhage
- History of hemorrhage with Hemoglobin > 3g /dl requiring transfusion, vasoactive treatment or surgery
- Known hereditary or acquired coagulation disorder
- Thrombocytopenia (platelets < 50 giga/L)
- Acute kidney injury (clairance < 15 ml/min selon MDRD - Modification of Diet in Renal Disease),
- Liver cirrhosis or acute liver failure (PTT<50%),
- Severe uncontrolled heart failure
- Persistente severe hypertension (PAS > 180mmHg)
- Patient with mastocytosis
- Person not affiliated to a national social security scheme
- Patient under court protection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:実験的
|
Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days. |
|
プラセボコンパレーター:コントロール
|
patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
全死因死亡
時間枠:無作為化後90日
|
無作為化後90日
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。